Tricor Medication Guide

Active Ingredient Description

Tricor contains fenofibrate as its active ingredient. Fenofibrate belongs to a class of medications called fibrates. It works by increasing the natural substance that breaks down fats in the blood, which helps to lower cholesterol and triglycerides levels. This reduction helps decrease the risk of atherosclerosis, heart attack, and stroke.

Pharmacodynamics

Fenofibrate primarily acts on liver peroxisome proliferator-activated receptor alpha (PPARα). Activation of PPARα increases lipolysis and elimination of triglyceride-rich particles from plasma. It increases the synthesis of lipoprotein lipase and reduces the level of apolipoprotein C-III, an inhibitor of lipoprotein lipase activity. This pharmacodynamic action aids in lowering lipid levels in the bloodstream.

Pharmacokinetics

Upon oral administration, fenofibrate is rapidly hydrolyzed to its active metabolite, fenofibric acid. It reaches peak plasma concentration in about 4-5 hours. Fenofibric acid is excreted mainly via the urine. The elimination half-life is approximately 20 hours. Food enhances the absorption of the drug, hence it is usually recommended to be taken with meals.

Indications and Usage

Tricor is indicated for the treatment of severe hypertriglyceridemia, mixed dyslipidemia, and primary hypercholesterolemia. It is also used in patients who have not responded adequately to diet control and other non-pharmacological measures. Tricor can also be used as an adjunct to diet therapy in managing lipid disorders.

Dosage and Administration

The recommended dose of Tricor is 145 mg once daily, taken with meals to enhance absorption. For patients with renal impairment, a lower starting dose of 48 mg daily is advised, with adjustments based on tolerance and response. Regular monitoring of lipid levels is essential to adjust the dose for optimal efficacy.

Contraindications

Tricor is contraindicated in patients with severe renal impairment, liver disease, pre-existing gallbladder disease, and known hypersensitivity to fenofibrate or any component of the formulation. Additionally, it should not be used in pediatric patients and during breastfeeding.

Drug Interactions

Co-administration with anticoagulants such as warfarin can increase bleeding risk, requiring careful monitoring of INR levels. Combining Tricor with other cholesterol-lowering drugs like statins increases the risk of myopathy and rhabdomyolysis. It also interacts with bile acid sequestrants, which may reduce its efficacy, necessitating a different administration schedule.

Adverse Effects

Potential adverse effects include abdominal pain, nausea, elevated liver enzymes, and headache. Serious but rare side effects include myopathy, rhabdomyolysis, and pancreatitis. Regular monitoring of liver function tests, kidney function, and lipid levels is recommended to detect any adverse effects early.

Storage Conditions

Store Tricor at room temperature between 20°C to 25°C (68°F to 77°F). Protect it from light and moisture. Keep it in a tightly closed container, out of reach of children and pets. Dispose of any unused or expired medication responsibly.

Clinical Trials

Clinical trials have demonstrated that fenofibrate reduces the risk of cardiovascular events in patients with type 2 diabetes and dyslipidemia. In studies, it has shown significant reductions in total cholesterol, LDL cholesterol, and triglycerides, with modest increases in HDL cholesterol. Tricor’s efficacy in primary prevention of cardiovascular events in patients without existing cardiovascular disease is still being studied.

Mechanism of Action

Tricor acts through modulating gene expression involved in lipid metabolism. By activating PPARα, it alters the transcription of genes responsible for lipoprotein metabolism. This mechanism increases the removal of triglycerides from the bloodstream and decreases the synthesis of VLDL cholesterol.

Special Population Considerations

In elderly patients, no dose adjustment is typically needed, but renal function should be assessed regularly. The safety and efficacy of Tricor in pediatric populations have not been established. In pregnant women, its use should only be considered if the potential benefits justify the potential risks to the fetus.

Monitoring Parameters

Monitoring hepatic function regularly is critical while on Tricor due to potential liver enzyme elevation. Kidney function should also be assessed periodically, particularly in patients with renal impairment. Regular lipid panel tests are necessary to track the efficacy and adjust the dose as required.

Patient Counseling Information

Patients should be informed about the importance of adhering to prescribed diet and exercise regimens alongside Tricor therapy. Emphasize the potential for muscle pain and the need to report any unusual symptoms promptly. Educate about the possible interactions with other medications, especially blood thinners and other cholesterol-lowering drugs.

Laboratory Test Interferences

Tricor can influence certain laboratory test results, particularly liver function tests, creating a need for regular monitoring. It may also affect creatinine levels, necessitating kidney function tests. Healthcare providers should be aware of these potential interferences and interpret test results accordingly.

Off-label Uses

Although not officially approved, Tricor is sometimes used off-label for conditions like nonalcoholic fatty liver disease (NAFLD) due to its lipid-lowering properties. Research is ongoing to explore its efficacy in other lipid-related conditions, offering potential new therapeutic avenues.

Comparative Efficacy

Tricor shows similar efficacy to other fibrates in lowering triglycerides and modestly improving HDL cholesterol. Compared to statins, it is usually less effective at lowering LDL cholesterol but holds significant value in managing triglyceride-rich dyslipidemia when used alone or in combination with statins.